TITLE

Felodipine/Metoprolol: A Review of the Fixed Dose Controlled Release Formulation in the Management of Essential Hypertension

AUTHOR(S)
Haria, M.; Plosker, G.L.; Markham, A.
PUB. DATE
January 2000
SOURCE
Drugs;Jan2000, Vol. 59 Issue 1, p141
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The main objective of fixed dose combination therapy for hypertension is to improve blood pressure (BP) control with lower, better tolerated dosages of 2 antihypertensives rather than higher dosages of a single agent. Felodipine and metoprolol lower BP via different, but complementary, mechanisms and controlled release formulations of these 2 drugs are available as a fixed dose combination, felodipine/metoprolol. In clinical trials in patients with hypertension, felodipine/metoprolol was significantly more effective than placebo and the respective monotherapies administered at the same dosages. Mean BP was reduced to <155/90mm Hg in patients treated with combination therapy and controlled in ≈70% of patients. In one study that titrated dosages to effect, fewer felodipine/metoprolol than felodipine or metoprolol monotherapy recipients required dosage increases to achieve BP control (45 vs 60 and 67%, respectively). Data from double blind comparative studies show that the antihypertensive efficacy of felodipine/metoprolol 5 to 10/50 to 100 mg/day is significantly greater than that of enalapril monotherapy or captopril plus hydrochlorothiazide and equivalent to nifedipine/atenolol and amlodipine. In comparisons with enalapril, fewer felodipine/metoprolol than enalapril recipients required dosage titration to achieve BP control. Compared with amlodipine, felodipine/metoprolol significantly reduced mean 24-hour average BP (8.9/5.5 vs 14.4/9.5mm Hg after 6 weeks; p < 0.001). Both treatments preserved diurnal rhythm. Long term follow-up studies show that the antihypertensive effect of felodipine/metoprolol occurs mostly during the first month of treatment with small additional decreases in BP being observed in the second and third months, and a relatively constant effect thereafter. According to a validated questionnaire, quality of life was relatively similar during 12 weeks treatment with felodipine/metoprolol, enalapril or placebo. In a retrospective pharmacoeconomic analysis conducted in Sweden, felodipine/metoprolol was more cost effective than enalapril as initial treatment for hypertension. Peripheral oedema, headache and flushing were the most commonly reported adverse events with felodipine/metoprolol and felodipine monotherapy, whereas dizziness, fatigue, headache and respiratory infection were more frequent with metoprolol monotherapy. Dose-dependent adverse events such as oedema may occur less often in patients taking lower dosages in combination than in those taking higher dosages of felodipine monotherapy. Thus, patients with hypertension treated with felodipine/metoprolol experience greater control of BP, with less need for dosage titration, than those treated with felodipine, metoprolol or enalapril monotherapy. Importantly this greater efficacy does not appear to be associated with a higher incidence of adverse events relative to monotherapy. Additionally, in short term studies felodipine/metoprolol had a similar (minimal) effect on QOL to enalapril monotherapy but was more cost effective.
ACCESSION #
9592957

 

Related Articles

  • Efficacy and Tolerability of Candesartan Cilexetil Monotherapy or in Combination with Other Antihypertensive Drugs: Results of the AURA Study. Schulte, K.; Fischer, M.; Lenz, T.; Meyer-Sabellek, W. // Clinical Drug Investigation;1999, Vol. 18 Issue 6, p453 

    Objective: To evaluate the efficacy and tolerability of different dosages of candesartan cilexetil administered as monotherapy or in combination with any pre-existing but insufficient antihypertensive treatment. The effects of candesartan cilexetil treatment on quality of life were also...

  • Tolerability of Antihypertensive Medications in Older Adults. Dharmarajan, Thiruvinvamalai; Dharmarajan, Lekshmi // Drugs & Aging;Oct2015, Vol. 32 Issue 10, p773 

    Several guidelines for hypertension have recently undergone revisions to incorporate an approach providing choices of medications based on age, race, and specific situations where hypertension may co-exist with disorders such as diabetes, coronary artery disease, heart failure and chronic kidney...

  • DESIGN AND OPTIMISATION OF EXTENDED RELEASE METOPROLOL SUCCINATE FORMULATION USING MELT GRANULATION TECHNIQUE. SHARMA, VANITA J.; AMIN, PURNIMA D. // International Journal of Pharmacy & Pharmaceutical Sciences;2013 Supplement, Vol. 5 Issue Supp 3, p230 

    Metoprolol succinate (M.succinate), a BCS Class I drug is the most widely prescribed anti-hypertensive drug and is considered to be safe. Owing to its high solubility, fabrication of an extended release matrix formulation becomes extremely challenging. Hydrophilic matrix polymers are the...

  • EFECTUL ASOCIERII INHIBITORILOR DE ENZIMÄ‚ DE CONVERSIE ÅžI A SARTANILOR LA IVABRADINÄ‚ VERSUS METOPROLOL ASUPRA PRINCIPALILOR PARAMETRI DOPPLER AI FLUXULUI TRANSMITRAL, LA DIABETICI CU FRACÅ¢IE DE E JECÅ¢IE PÄ‚STRATÄ‚. MOGA, RODICA; MANIŢIU, IOAN // Acta Medica Transilvanica;mar2013, Vol. 18 Issue 1, p59 

    Within a larger study of the effect of ivabradine versus metoprolol on the main Doppler parameters of the mitral inflow in diabetic patients with normal ejection fraction, we studied the outcome of these parameters in relation with the association or non-association of angiotensin-converting...

  • Betaloc.  // Royal Society of Medicine: Medicines;2002, p111 

    The article presents information on Betaloc, a proprietary, prescription-only preparation drug of the beta-blocker metoprolol tartrate. This drug can be used as an antihypertensive for high blood pressure, as an anti-angina treatment to relieve symptoms and improve exercise tolerance...

  • Betaloc-SA.  // Royal Society of Medicine: Medicines;2002, p112 

    The article presents information on Betaloc-SA, a proprietary, prescription-only preparation drug of the beta-blocker metoprolol tartrate. This drug can be used as an antihypertensive for high blood pressure and as an antimigraine treatment to prevent attacks.

  • Lopresor SR.  // Royal Society of Medicine: Medicines;2002, p341 

    This article presents information on the Lopresor SR which is a proprietary, prescription-only preparation of the beta-blocker metoprolol tartrate. It can be used as an antihypertensive for raised blood pressure. The drug is available as modified-release tablets.

  • Review: β-blockers are less effective than other antihypertensive drugs for reducing risk for stroke in primary hypertension: COMMENTARY. Rudd, Peter // ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p67 

    The article presents comments of the author on a study which found that β-blockers are less effective than other antihypertensive drugs for reducing risk for stroke in primary hypertension. Despite their traditional place in antihypertensive pharmacology, β-blockers have received mixed...

  • Effect of blood pressure on plasma volume loss in the rat under increased permeability. Dubniks, Maris; Persson, Johan; Grände, Per-Olof; Grände, Per-Olof // Intensive Care Medicine;Dec2007, Vol. 33 Issue 12, p2192 

    Objective: To evaluate the effects of change in blood pressure on plasma volume under increased permeability.Design: Prospective randomized laboratory study.Subject: Sixty-one adult male Sprague-Dawley rats.Interventions: Permeability was...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics